TNFSF13B and systemic lupus erythematosus: Medications that modulate and deplete B lymphocytes are used in selected patients with severe pathology and high activity; for example, rituximab, a monoclonal antibody, is prescribed in an off-label manner as a second-line agent [6, 7], and belimumab (approved in Colombia in October 2014), a B-lymphocyte stimulator (BLyS)-specific inhibitor, is indicated for the treatment of adult patients with active, autoantibody-positive SLE who are receiving standard therapy [7, 8].